Latest Period
Q4 2025
Security Snapshot
RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) Institutional Ownership
CUSIP: 75382E208
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
99
Shares (Excl. Options)
27,200,695
Price
$33.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Symbol
- RAPT
- Shares outstanding
- 27,748,559
- Price per share
- $58.02
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 27,200,695
- Total reported value
- $921,288,979
- % of total 13F portfolios
- 0.01%
- Share change
- +13,577,455
- Value change
- +$461,871,577
- Number of holders
- 99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RAPT - RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 75382E208.
- 99 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 99 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $921,288,979 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 99 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 75382E208?
CUSIP 75382E208 identifies RAPT - RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75382E208:
Significant Owners of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ForGrowth III PA B.V. | 7.4% | $47,291,008 | 1,833,333 | ForGrowth III PA B.V. | 23 Oct 2025 | |||
| Redmile Group, LLC | 9.9% | $14,934,463 | 1,765,303 | Redmile Group, LLC | 30 Jun 2025 | |||
| RTW INVESTMENTS, LP | 5.9% | $55,041,487 | 1,637,165 | RTW Investments, LP | 31 Dec 2025 | |||
| VANGUARD GROUP INC | 4.2% | $17,958,239 | 696,188 | The Vanguard Group | 30 Sep 2025 | |||
| Nantahala Capital Management, LLC | 3.8% | -33% | $16,074,692 | -$8,467,788 | 623,282 | -35% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| Deep Track Capital, LP | 0.4% | $3,713,262 | 110,448 | Deep Track Capital, LP | 31 Dec 2025 |
As of 31 Dec 2025, 99 institutional investors reported holding 27,200,695 shares of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT). This represents 98% of the company’s total 27,748,559 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.3% | 2,582,408 | +58% | 2.9% | $87,466,159 |
| FCPM III SERVICES B.V. | 6.6% | 1,833,333 | +433% | 8.1% | $62,094,989 |
| ORBIMED ADVISORS LLC | 5.9% | 1,642,891 | +51% | 1.2% | $55,644,718 |
| RTW INVESTMENTS, LP | 5.9% | 1,637,165 | +11% | 0.56% | $55,450,779 |
| Foresite Capital Management VI LLC | 5.6% | 1,562,500 | 0% | 16% | $52,921,875 |
| Siren, L.L.C. | 5% | 1,375,000 | +137% | 1.4% | $46,571,250 |
| VANGUARD GROUP INC | 4.3% | 1,186,791 | +70% | 0% | $40,196,611 |
| Frazier Life Sciences Management, L.P. | 3.5% | 983,333 | 0.89% | $33,305,489 | |
| BRAIDWELL LP | 3.4% | 929,694 | 1% | $31,488,736 | |
| Redmile Group, LLC | 3.2% | 885,927 | +60% | 2.2% | $30,006,347 |
| PERCEPTIVE ADVISORS LLC | 3% | 825,890 | +349% | 0.51% | $27,972,894 |
| Soleus Capital Management, L.P. | 2.8% | 764,000 | +42% | 1.1% | $25,876,680 |
| Nantahala Capital Management, LLC | 2.7% | 754,153 | +21% | 1.5% | $25,543,162 |
| Ikarian Capital, LLC | 2.4% | 665,271 | +8.2% | 2.9% | $22,532,728 |
| Caligan Partners LP | 2.3% | 644,400 | 2% | $21,825,828 | |
| STATE STREET CORP | 2.3% | 639,804 | +1611% | 0% | $21,670,161 |
| CITADEL ADVISORS LLC | 2.1% | 591,802 | +3711% | 0.01% | $20,044,334 |
| GREAT POINT PARTNERS LLC | 2.1% | 581,187 | 6.4% | $19,684,804 | |
| Octagon Capital Advisors LP | 2.1% | 574,000 | 2.4% | $19,441,380 | |
| ADAR1 Capital Management, LLC | 1.8% | 509,679 | +0.38% | 1.3% | $17,262,828 |
| BlackRock, Inc. | 1.8% | 486,153 | +443% | 0% | $16,466,002 |
| BOONE CAPITAL MANAGEMENT LLC | 1.7% | 470,456 | -40% | 5% | $15,934,345 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.5% | 424,862 | +836% | 0.02% | $14,390,076 |
| MPM BIOIMPACT LLC | 1.4% | 397,906 | 1.5% | $13,477,076 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.4% | 390,747 | +75% | 0.35% | $13,234,601 |